Skip to Main Content

Impact of obesity and sedentary lifestyles on immune response to and clinical outcomes of immunotherapies

  • Study HIC#:2000032988
  • Last Updated:12/22/2022

This is a prospective observational study of BMI, physical activity, immune profiles, and immunotherapy-induced toxicity in patients newly diagnosed with breast cancer and initiating immunotherapy. Primary Endpoint: Physical activity Secondary Endpoint: Changes in Biomarkers and pathological complete response (pCR) Aim 1: Determine the feasibility of monitoring physical activity in patients with early-stage breast cancer undergoing immunotherapy plus chemotherapy. Aim 2: Evaluate serum obesity and cytokine/chemokine markers for associations with BMI and physical activity using Luminex/Olink panels. Aim 3: Determine if there are differences in gene expression from tumor tissue and/or blood immune cells associated with BMI and physical activity using RNAseq.

  • Start Date11/28/2022
  • End Date06/01/2023

Principal Investigator

For more information about this study, contact: